Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UCB | Brussels | Healthcare | Pharmaceuticals | €30.19B | 126.4x | -4.66 | €158.85 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
Tubize-Fin | Brussels | Healthcare | Pharmaceuticals | €5.82B | 66.2x | €130.60 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.5% Upside | Upgrade to Pro+ | ||
Fagron | Brussels | Healthcare | Pharmaceuticals | €1.39B | 17.9x | 1.16 | €18.94 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.4% Upside | Upgrade to Pro+ | |
Hyloris | Brussels | Healthcare | Pharmaceuticals | €164.64M | -21.3x | 0.34 | €5.98 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mithra Pharmaceuticals Sa | Brussels | Healthcare | Pharmaceuticals | €15.20M | -0.2x | €0.22 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -54.5% Downside | Upgrade to Pro+ | ||
Biosenic | Brussels | Healthcare | Pharmaceuticals | €2.09M | -0x | 0 | €0.008 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |